Technology in Anesthesiology

A study from the University of Michigan introduces a chip for processing blood samples to monitor cancer cells, providing an early assessment of efficacy by the fourth week of treatment. The technology aims to reduce the delay in evaluating cancer treatments, enabling timely adjustments to enhance outcomes and minimize unnecessary side effects. Current methods involve weeks to months of waiting before assessing treatment effectiveness. The “GO chip” utilizes graphene oxide sheets with antibodies to capture cancer cells, offering a more sensitive and continuous surveillance method compared to traditional approaches like CT scans or biopsies. In lung cancer cases, the chip successfully monitored patients undergoing chemotherapy and immunotherapy, revealing that at least 75% reduction in cancer cells by the fourth week indicated a higher likelihood of persistent cancer post-treatment. Additionally, the study identified activated genes in nonresponsive patients, suggesting potential targets for future therapies. The chip’s ability to quickly provide precise information may move cancer diagnostics toward personalized and adaptive treatment strategies.

Source: asamonitor.pub/3w375IX